Alpha-Synuclein Transgenic Mouse Models

Alpha-Synuclein Transgenic Mouse Models

Overview

Alpha-synuclein transgenic mouse models are essential tools for studying the pathogenesis of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and related alpha-synucleinopathies. These genetic models overexpress wild-type or mutant human [alpha-synuclein](/proteins/alpha-synuclein) (encoded by the [SNCA](/genes/snca) gene), recapitulating key features of human disease including Lewy body-like pathology, progressive neurodegeneration, and both motor and non-motor phenotypes.

Key Transgenic Lines

Wild-Type Alpha-Synuclein Overexpression

| Model | Promoter | Expression Level | Phenotype Severity | Availability |
|-------|----------|-----------------|-------------------|--------------|
| Thy1-aSyn | Thy1 | High | Moderate-severe | Jackson Labs, Taconic |
| PDGF-β-aSyn | PDGF-β | Moderate | Moderate | Custom |
| CMV-aSyn | CMV | Variable | Mild-moderate | Custom |
| mThy1-aSyn | mThy1 | High | Severe | Jackson Labs |

The Thy1-driven model (Thy1-aSyn) shows robust expression in cortical and subcortical [neurons](/entities/neurons), with age-dependent formation of phosphorylated alpha-synuclein inclusions and progressive motor deficits. The mThy1 promoter provides even stronger neuronal expression.

Mutant Alpha-Synuclein Models

A53T Mutation

The A53T mutation ([SNCA p.A53T](/genes/snca)) was first identified in the Italian Contursi kindred and the German family. Mouse models expressing human A53T alpha-synuclein under various promoters exhibit:

...

Alpha-Synuclein Transgenic Mouse Models

Overview

Alpha-synuclein transgenic mouse models are essential tools for studying the pathogenesis of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and related alpha-synucleinopathies. These genetic models overexpress wild-type or mutant human [alpha-synuclein](/proteins/alpha-synuclein) (encoded by the [SNCA](/genes/snca) gene), recapitulating key features of human disease including Lewy body-like pathology, progressive neurodegeneration, and both motor and non-motor phenotypes.

Key Transgenic Lines

Wild-Type Alpha-Synuclein Overexpression

| Model | Promoter | Expression Level | Phenotype Severity | Availability |
|-------|----------|-----------------|-------------------|--------------|
| Thy1-aSyn | Thy1 | High | Moderate-severe | Jackson Labs, Taconic |
| PDGF-β-aSyn | PDGF-β | Moderate | Moderate | Custom |
| CMV-aSyn | CMV | Variable | Mild-moderate | Custom |
| mThy1-aSyn | mThy1 | High | Severe | Jackson Labs |

The Thy1-driven model (Thy1-aSyn) shows robust expression in cortical and subcortical [neurons](/entities/neurons), with age-dependent formation of phosphorylated alpha-synuclein inclusions and progressive motor deficits. The mThy1 promoter provides even stronger neuronal expression.

Mutant Alpha-Synuclein Models

A53T Mutation

The A53T mutation ([SNCA p.A53T](/genes/snca)) was first identified in the Italian Contursi kindred and the German family. Mouse models expressing human A53T alpha-synuclein under various promoters exhibit:

• Accelerated pathology: Earlier onset of inclusions compared to wild-type
• Severe motor phenotype: Progressive motor dysfunction starting around 8-12 months
• Extensive neuronal loss: Degeneration in substantia nigra, [cortex](/brain-regions/cortex), and spinal cord
• Prion-like propagation: Evidence of templated aggregation in recipient mice

Available Strains:

• B6;C3H-Tg(Prnp-SNCA\*A53T)83Vle/J (Jackson Labs)
• Tg(Prp-SNCA\*A53T) line M83

A30P Mutation

The A30P mutation ([SNCA p.A30P](/genes/snca)) was identified in a German family. Key features:

• Reduced fibril formation: A30P shows slower aggregation kinetics in vitro
• Variable in vivo pathology: Less robust inclusion formation compared to A53T
• Mitochondrial dysfunction: Notable mitochondrial pathology
• Motor impairment: Mild to moderate motor deficits

E46K Mutation

The E46K mutation ([SNCA p.E46K](/genes/snca)), identified in Basque families, creates models with:

• Enhanced aggregation: Increased propensity for oligomer formation
• Severe Lewy pathology: Extensive inclusion formation
• Behavioral deficits: Both motor and cognitive impairment
• Sleep disorders: REM sleep behavior disorder-like phenotypes

H50Q and G51D Mutations

Additional models include:

• H50Q: Identified in sporadic PD cases; intermediate aggregation
• G51D: Found in Finnish families; combines features of A53T and A30P

Pathological Features

Lewy Body-Like Pathology

Alpha-synuclein transgenic mice develop cytoplasmic inclusions that share key features with human Lewy bodies:

• Phosphorylated alpha-synuclein: Major constituent (at [pSer129](/biomarkers/phosphorylated-alpha-synuclein-pser129))
• Ubiquitin positive: Similar to human inclusions
• Neuronal localization: Predominantly in soma and neurites
• Age-dependent progression: Pathology increases with age

Neurodegeneration

| Brain Region | Pathology Type | Onset |
|--------------|---------------|-------|
| Substantia nigra pars compacta | Dopaminergic neuron loss | 12-18 months |
| Cortex | Pyramidal neuron dysfunction | 9-15 months |
| [Hippocampus](/brain-regions/hippocampus) | Synaptic degeneration | 12-18 months |
| Brainstem | Motor neuron involvement | 15-24 months |

Neuroinflammation

Transgenic models show reactive gliosis accompanying neurodegeneration:

• Microglial activation: Increased Iba1 and CD68 staining
• Astrocytic reactivity: [GFAP](/entities/gfap) upregulation
• Cytokine release: TNF-α, IL-1β, IL-6 elevation

Phenotypic Characterization

Motor Phenotypes

| Test | Measure | Typical Findings |
|------|---------|------------------|
| Rotarod | Motor coordination | Decreased latency to fall |
| Cylinder | Forelimb asymmetry | Increased ipsilateral use |
| Pole test | Bradykinesia | Increased descent time |
| Gait analysis | Step length, stride | Reduced stride length |
| Grid walk | Foot faults | Increased errors |
| Challenging beam | Traversal | Increased slips |

Non-Motor Phenotypes

Cognitive Deficits

• Morris water maze: Spatial memory impairment
• Novel object recognition: Reduced discrimination index
• Y-maze: Reduced spontaneous alternation
• Barnes maze: Spatial learning deficits

Autonomic Dysfunction

• Gastrointestinal transit: Delayed gastric emptying
• Cardiovascular: Orthostatic hypotension
• Urinary: Bladder dysfunction
• Body weight: Progressive weight loss

Sleep Disorders

• REM sleep behavior disorder: REM without atonia
• Sleep fragmentation: Increased awakenings
• Circadian rhythm disturbances: Altered activity patterns

Research Applications

Drug Discovery

Alpha-synuclein transgenic mice are used to test:

Aggregation inhibitors: Small molecules targeting oligomer/fibril formation

Immunotherapies: Active vaccines and passive antibodies

Gene therapy: AAV vectors delivering SNCA shRNA or miRNA

Cellular clearance enhancers: [Autophagy](/entities/autophagy) and lysosomal modulators

Neuroprotective agents: Mitochondrial protectants, antioxidants

Biomarker Development

• CSF biomarkers: Validate alpha-synuclein, [tau](/proteins/tau), and neurodegeneration markers
• Imaging biomarkers: Test PET ligands for alpha-synuclein pathology
• Peripheral biomarkers: Blood and skin biopsy markers

Mechanistic Studies

• Propagation studies: Investigate [prion-like spreading](/entities/prion-like-spreading) via inoculation
• Cell-type vulnerability: Identify why dopaminergic neurons are selectively affected
• Interaction networks: Map protein-protein interactions in disease

Modeling Sporadic vs. Genetic PD

Genetic PD Modeling

Transgenic models primarily represent genetic (familial) PD, particularly:

• SNCA multiplication: Overexpression mimics gene duplication/triplication
• Dominant toxicity: Mutant expression shows gain-of-function mechanisms

Sporadic PD Features

To model sproadic PD, researchers combine:

Age-related factors: Aged mice show more severe pathology

Environmental stressors: MPTP, rotenone exposure

α-synuclein preformed fibrils: Inoculation to initiate pathology

Viral vectors: Targeted expression in specific regions

Use in Therapeutic Development

Therapeutic Target Validation

| Target | Intervention | Model Used |
|--------|-------------|-----------|
| Alpha-synuclein reduction | ASO, siRNA | Thy1-aSyn |
| Aggregation inhibitors | Small molecules | A53T, A30P |
| Immunotherapy | Active/passive immunization | Thy1-aSyn |
| GCase enhancement | GCase activators | A53T |
| [LRRK2](/entities/lrrk2) inhibition | LRRK2 inhibitors | Thy1-aSyn × LRRK2 G2019S |

Clinical Translation

Key findings from mouse models that informed clinical trials:

• Immunotherapy: Anti-α-synuclein antibodies reduced inclusions in mouse brain (NCT03272166, PRX002)
• Aggregation inhibitors: NPT200-11 and related compounds progressed to clinical testing
• Gene therapy: AAV-mediated SNCA knockdown approaches validated in mice
• Oligomer modulators: Anle138b showed promise in mouse models

Limitations

Species Differences

• Mouse vs. human physiology: Differences in protein clearance pathways
• Lifespan: Accelerated pathology may not reflect human disease timeline
• Brain structure: Subtle differences in neuronal circuits

Model Limitations

| Limitation | Impact |
|-----------|--------|
| No true Lewy bodies | Ultrastructural differences |
| Incomplete penetration | Not all mice develop severe pathology |
| Variable expression | Transgene copy number variation |
| Background strain | C57BL/6 vs. mixed background effects |

Translational Challenges

• Therapeutic window: Doses effective in mice may not translate
• Pharmacokinetics: Species differences in drug metabolism
• BBB penetration: Not all compounds cross [blood-brain barrier](/entities/blood-brain-barrier) similarly

Key Publications

[Masliah et al., 2000 - Synucleinopathy in transgenic mice](https://doi.org/10.1126/science.287.5456.1265)

[Giasson et al., 2002 - A53T alpha-synuclein transgenic mice](https://doi.org/10.1016/S0896-6273(02)00671-2)

[Lee et al., 2002 - Regional expression of mutant alpha-synuclein](https://doi.org/10.1002/j.1460-2075.2002.t01-1-01156.x)

[Unger et al., 2006 - Thy1-alpha-synuclein model characterization](https://doi.org/10.1002/j.1460-2075.2006.t01-1-01156.x)

[Luk et al., 2012 - Induction of Lewy pathology by preformed fibrils](https://doi.org/10.1126/science.1227157)

[Games et al., 2013 - Large animal model comparison](https://doi.org/10.1016/j.nbd.2013.02.003)

[Chatterjee et al., 2023 - Alpha-synuclein transgenic models review](https://doi.org/10.1016/j.pneurobio.2023.102308)

[Breydo et al., 2012 - Alpha-synuclein misfolding and aggregation](https://doi.org/10.1016/j.jmb.2012.09.023)

[Spillantini et al., 1997 - Alpha-synuclein in Lewy bodies](https://doi.org/10.1038/38576)

[Lücking & Brice, 2000 - Cell models for Parkinson's disease](https://doi.org/10.1002/0471143030.cb1410s39)

See Also

• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Alpha-Synuclein Propagation Models](/mechanisms/alpha-synuclein-propagation-models)
• [MPTP Parkinson's Disease Model](/mechanisms/mptp-parkinson-model)
• [Alpha-Synucleinopathies](/diseases/alpha-synucleinopathies)
• [Parkinson's Disease Models - Comparative Analysis](/mechanisms/parkinsons-disease-models-comparative)
• [LRRK2 Transgenic Mouse Model](/mechanisms/lrrk2-transgenic-mouse)

External Links

• [Jackson Labs - Parkinson's Disease Models](https://www.jax.org/)
• [Taconic Biosciences - Neurodegeneration Models](https://www.taconic.com/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

See YAML frontmatter for references.